Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Innovent Biologics (Suzhou) Co. Ltd. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 7 pending office actions. These actions are distributed among 7 distinct examiners, indicating a broad range of individual reviews for the company's applications. The prosecution activity spans 4 distinct art units, which shows that the company's technical filings are diverse enough to be categorized across multiple specialized groups within the patent office.
The busiest examiner for this portfolio is CUNNINGCHEN, KATHLEEN MARY, who is currently handling 1 busiest examiner pending office action. This suggests an even distribution of work across the 7 distinct examiners. With 7 pending office actions and 4 distinct art units, the portfolio demonstrates a significant level of activity in the Biotechnology & Pharmaceuticals sector. This distribution requires managing multiple examiner relationships and adhering to the specific practices of several different art units simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558655 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | REDDIG, PETER J | — |
| 18262937 | SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF | HAUK TEODORO, PRICILA NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681904 | ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18294212 | ANTI-CD79BxCD3 BISPECIFIC ANTIBODY AND USE THEREOF | LEE, YIE CHIA | — |
| 18573602 | USE OF MAZDUTIDE | D' AMBROSIO, THEA | — |
| 18566197 | BISPECIFIC BINDING MOLECULE BINDING TO VEGF AND ANG2 AND USE THEREOF | SZPERKA, MICHAEL EDWARD | — |
| 18558655 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1646 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681904 | ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — | §112DP | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18294212 | ANTI-CD79BxCD3 BISPECIFIC ANTIBODY AND USE THEREOF | LEE, YIE CHIA | — | §112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18573602 | USE OF MAZDUTIDE | D' AMBROSIO, THEA | 1654 | §102§103§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18566197 | BISPECIFIC BINDING MOLECULE BINDING TO VEGF AND ANG2 AND USE THEREOF | SZPERKA, MICHAEL EDWARD | — | §112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18558655 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | REDDIG, PETER J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18262937 | SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF | HAUK TEODORO, PRICILA NMN | 1645 | §102§112 | Non-Final OA | — | Pending | Jul 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial